Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lesly Robinson

Podiatrist Wilmington, DE Doctor of Podiatric Medicine

NPI 1629081922 CMS profile 210091

4011 N Market Street, Wilmington, DE 19802

Open in the dashboard

General payments

$3,289

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$99,115 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Lesly Robinson of Wilmington, DE is reported in the CMS Open Payments database as having received $3,289 across 91 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $99,115 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $498 15
2024 General $244 12
2023 General $435 25
2022 General $112 6
2021 General $151 10
2020 General $81 4
2019 General $1,767 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lesly Robinson
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Lesly Robinson were reported at $498. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Lesly Robinson Podiatrist median Middle half National median
2019 $1,767 $196 $72–$601 $163
2020 $81 $118 $38–$335 $114
2021 $151 $169 $57–$573 $132
2022 $112 $220 $74–$782 $149
2023 $435 $208 $71–$635 $160
2024 $244 $237 $87–$681 $164
2025 $498 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Osiris Therapeutics Inc. $1,526 3 payments
  2. Smith+Nephew, Inc. $768 50 payments
  3. Organogenesis Inc. $305 12 payments
  4. Kerecis Limited $147 1 payment
  5. Reapplix Inc. $58 2 payments
  6. Alexion Pharmaceuticals, Inc. $58 2 payments
  7. Solventum Corporation $50 2 payments
  8. Celgene Corporation $45 2 payments
  9. BTG International, Inc. $42 2 payments
  10. Integra LifeSciences Corporation $41 2 payments
  11. Other $249 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,789 90 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 1 payment
Products named General payments · program years 2019–2025
  1. Stravix $1,582 8 payments
  2. GRAFIX $1,536 4 payments
  3. GrafixPL $1,536 4 payments
  4. GRAFIX PL $310 10 payments
  5. OASIS $212 4 payments
  6. COLLAGENASE SANTYL $208 21 payments
  7. Puraply $169 8 payments
  8. Kerecis SurgiClose Wound Care $147 1 payment
  9. Kerecis SurgiClose Wound Care $147 1 payment
  10. Kerecis SurgiClose Wound Care $147 1 payment
  11. Other $1,473 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

478

Median for Podiatry: 160

Drug cost

$10,129

Median for Podiatry: $2,368

Branded share of claims

5.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 179 $4,319
Ammonium Lactate Generic 122 $2,521
Ketoconazole Generic 127 $2,473
Clindamycin Phosphate Generic 13 $337
Ciclopirox Ciclopirox Olamine Brand 12 $222
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $184
Duloxetine Hcl Generic 11 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$15,381

Medicare's payments for the services billed

Medicare patients

95

Average age 73

Services billed

284

62 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 67%
Arthritis 49%
Chronic kidney disease 41%
Ischemic heart disease 38%
Heart failure 22%
Depression 19%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record